| __timestamp | Genmab A/S | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 79529000 | 5078000000 |
| Thursday, January 1, 2015 | 91224000 | 4717000000 |
| Friday, January 1, 2016 | 102413000 | 5096000000 |
| Sunday, January 1, 2017 | 146987000 | 4986000000 |
| Monday, January 1, 2018 | 213695000 | 4214000000 |
| Tuesday, January 1, 2019 | 342000000 | 3806000000 |
| Wednesday, January 1, 2020 | 661000000 | 3671000000 |
| Friday, January 1, 2021 | 1283000000 | 3528000000 |
| Saturday, January 1, 2022 | 2676000000 | 3445000000 |
| Sunday, January 1, 2023 | 3297000000 | 3498000000 |
| Monday, January 1, 2024 | 3790000000 | 3702000000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical industry, operational efficiency is key to maintaining a competitive edge. Over the past decade, Teva Pharmaceutical Industries Limited and Genmab A/S have showcased contrasting trends in their Selling, General, and Administrative (SG&A) expenses.
Teva, a global leader in generic medicines, has seen a consistent reduction in SG&A expenses, dropping from a peak in 2016 to a 32% decrease by 2023. This trend reflects Teva's strategic cost-cutting measures amidst challenging market conditions.
Conversely, Genmab, a biotechnology innovator, has experienced a staggering 4,000% increase in SG&A expenses since 2014. This surge aligns with Genmab's aggressive expansion and investment in research and development, positioning itself as a frontrunner in antibody therapeutics.
These divergent paths highlight the distinct strategies of two industry giants, offering valuable insights into their operational priorities and market positioning.
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Intra-Cellular Therapies, Inc.
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Dr. Reddy's Laboratories Limited
SG&A Efficiency Analysis: Comparing Teva Pharmaceutical Industries Limited and Ascendis Pharma A/S
Teva Pharmaceutical Industries Limited vs Corcept Therapeutics Incorporated: SG&A Expense Trends
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Xenon Pharmaceuticals Inc.
Breaking Down SG&A Expenses: Teva Pharmaceutical Industries Limited vs HUTCHMED (China) Limited
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Ligand Pharmaceuticals Incorporated
BeiGene, Ltd. and Genmab A/S: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Genmab A/S vs Madrigal Pharmaceuticals, Inc.
Genmab A/S and Pharming Group N.V.: SG&A Spending Patterns Compared
Genmab A/S or Jazz Pharmaceuticals plc: Who Manages SG&A Costs Better?
Genmab A/S or Amicus Therapeutics, Inc.: Who Manages SG&A Costs Better?